Drug intelligence / Profile preview

OC-101

Development stage: Preclinical
Lead developer: Viatris
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intranasal, Intralacrimal Gland

Overview

OC-101 is a preclinical gene therapy candidate being developed for various eye conditions. It was part of Oyster Point Pharma's ophthalmology pipeline, which was acquired by Viatris. The drug is intended to address unmet needs in eye care, leveraging gene therapy technology.

Other names: AAV-NGFOC-101 AAV-NGFOC101 AAV-NGFOC 101 AAV-NGF

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on OC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC-101.

Explore the full profile